Commenting on news that Orexo AB has won its patent appeal with Teva over its Zubsolv opioid addiction drug, Stephen McNeeney, partner and pharmaceuticals expert, says:
This is a hugely significant and business-critical verdict for our client, Orexo. We are pleased that the Court of Appeal in the US recognised Zubsolv's novel formulation was not suggested by the prior art and provided significant improvements over it. The way is now clear for Zubsolv to play a significant role in helping healthcare providers tackle the growing opioid addiction challenge across the US and beyond."
